SIR, AdvaMed, Philips, Abbott and others in the Office-Based Facility Association contend more must be done to reverse these trends and protect private practices.
Just because a healthcare AI product gets loudly promoted doesn’t mean its claims are bogus. The salient question is whether or not it performs as well in a clinical setting as it did in a research lab—or in a marketer’s mind.
The Missouri complaint mirrors those brought by the Federal Trade Commission, the state of Texas and Philadelphia-based Jefferson Health, among others, in that it’s focused on alleged collusion between pharmacy benefit managers and drug companies to control the price of insulin.
Vapor 2000 and Vapor 3000 devices manufactured by Draegar were improperly cleaned after parts were soldered on, meaning toxic metals could mix with medical gases. Due to the high risk posed to patient health, this recall has earned the FDA’s most serious designation.
Boston Scientific sent all known customers a letter on December 19, 2025 alerting them to an issue with certain AXIOS Stent and Electrocautery Enhanced Delivery Systems. During deployment, the stents may not expand. This can cause severe, potentially life-threatening injury to patients. All recalled stents must be removed from clinical settings immediately.
An interventional rad in California is at risk of having his medical license revoked after the state’s medical board discovered he had previously omitted information about his past.
Michael J. Reardon, MD, shared the highly anticipated data with a large audience at ACC.25 in Chicago. Overall, he said, these five-year findings suggest TAVR with a supra-annular, self-expanding valve is a safe and effective alternative to SAVR.
There are at least 65 consolidated cases pending in federal courts that stem from the 2024 data breach on the claims processor's network. A judge in Minnesota has asked that the lawsuits be coordinated and consolidated as much as possible.
Researchers still think patients should receive an injectable version of semaglutide when possible, but new data out of ACC.25 confirm that an oral formulation of the drug is associated with significant benefits.
Patients who present with type 2 diabetes and PAD often face substantial mobility issues. According to new data presented at ACC.25, however, treatment with semaglutide could represent a major step forward for this high-risk population.
SIR, AdvaMed, Philips, Abbott and others in the Office-Based Facility Association contend more must be done to reverse these trends and protect private practices.
